ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ensysce Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.50−0.02 (-2.97%)
Close on Oct 19, 2026
- Market cap
- $6.56M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.8771 (−78.87%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Ensysce Biosciences, Inc. saw revenue fall 39.3% to $4.50M over the twelve months to Jun 30, 2026. Free cash flow was -$7.93M.
Revenue
$4.50M
-39.3% vs. a year earlier
Operating income
-$12.66M
TTM Q2 2026
Free cash flow
-$7.93M
FY2025
EPS, diluted
-$2.75
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $6.56M
- P/E ratio
- –
- Price to sales
- 1.46
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -120.96%
Fundamentals
- Revenue
- $4.50M
- EPS, diluted
- -$2.75
- Free cash flow
- -$7.93M
- Book value per share
- -$0.06
- Diluted shares
- 13M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$4.50M-39.3% YoY
Operating income
-$12.66M
Net income
–
EPS, diluted
-$2.75
Free cash flow
–
Reported periodTrailing twelve months